GlassScriptPhysician profile
Lee Daniel Haas
NPI 1598113433
$95,092.25
in general payments reported to CMS, 2019-2025
28 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,711 · 2022: $17K · 2023: $29K · 2024: $20K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Food and Beverage: $8,255 · Consulting Fee: $7,658 · Travel and Lodging: $4,478 · Education: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,692.00 |
| Food and Beverage | $8,255.45 |
| Consulting Fee | $7,657.50 |
| Travel and Lodging | $4,478.31 |
| Education | $680.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $71,958.58 | 2021-2025 | Ebglyss, Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $6,450.23 | 2022-2025 | Sotyktu |
| Ucb, INC. | $3,957.84 | 2021-2025 | Bimzelx, Cimzia |
| Eli Lilly and Company | $3,637.86 | 2025 | Ebglyss |
| Abbvie INC. | $2,388.96 | 2021-2025 | |
| Janssen Biotech, INC. | $1,860.17 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,472.38 | 2021-2025 | |
| Galderma Laboratories, L.P. | $655.41 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Regeneron Healthcare Solutions, INC. | $552.53 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $449.62 | 2021-2025 | Winlevi, Absorica Ld, Odomzo |
| Genzyme Corporation | $330.21 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $275.91 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $232.08 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $225.65 | 2022-2025 | Otezla, Otezla |
| Pfizer INC. | $185.29 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $106.98 | 2022-2024 | Vtama |
| Incyte Corporation | $75.80 | 2022-2025 | Opzelura |
| Almirall LLC | $59.97 | 2022-2025 | Klisyri |
| Merz North America, INC. | $45.37 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.13 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.69 | 2023 | Siliq |
| Cipher Pharmaceuticals US LLC | $18.32 | 2025 | Natroba, Spinosad |
| Organon LLC | $17.05 | 2024 | |
| Journey Medical Corporation | $16.94 | 2022 | |
| Sandoz INC. | $15.48 | 2024 | Hyrimoz |
| Botanix Sb INC | $15.04 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $14.35 | 2021 | |
| Sebela Pharmaceuticals INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Haas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.